Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Baskent University |
---|---|
Information provided by: | Baskent University |
ClinicalTrials.gov Identifier: | NCT00300911 |
The present study aimed to evaluate the effect of rosiglitazone treatment on cardiac function compared with metformin
Condition | Intervention | Phase |
---|---|---|
Diabetes Mellitus, Type 2 |
Drug: Rosiglitazone(drug), cardiac adverse effects |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study |
Official Title: | A Study of PPAR-Gamma Agonist-Rosiglitazone for Determining Cardiac Adverse Effects in Type 2 Diabetic Patients |
Estimated Enrollment: | 45 |
Study Start Date: | December 2005 |
Large scale clinical trials have reported fluid retention and increase in plasma volume (6% to 7%) with glitazone therapy, with an increased incidence of peripheral edema occuring in 2% to 5% patients. Some evidence suggests that this effect may be related to increased endothelial cell permeability induced by glitazones therapy. Others report that glitazones may interfere with renal hemodynamics. In controlled clinical trials, the frequency of new onset congestive heart failure was very low in glitazones treated patients. The incidence of congestive heart failure is higher in patients receiving combination therapy with insulin and glitazones. Only few studies compared rosiglitazone and metformin on cardiac safety. Recently a study reported a reversible increase in endothelial cell permeability to albumin in cultured pulmonary arterial cells treated with rosiglitazone. To our knowledge, there is not any clinical study published for showing the reversibility of the cardiac adverse effects if the rosiglitazone treatment is continued.
Ages Eligible for Study: | 45 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | KA04/164 |
Study First Received: | March 9, 2006 |
Last Updated: | March 9, 2006 |
ClinicalTrials.gov Identifier: | NCT00300911 |
Health Authority: | Turkey: Ministry of Health |
Natriuretic Peptide, Brain Heart Failure, Congestive |
Natriuretic Peptide, Brain Ventricular Dysfunction Heart Failure Metabolic Diseases Heart Diseases Diabetes Mellitus Endocrine System Diseases |
Diabetes Mellitus, Type 2 Ventricular Dysfunction, Left Endocrinopathy Glucose Metabolism Disorders Metabolic disorder Rosiglitazone |
Hypoglycemic Agents Physiological Effects of Drugs Cardiovascular Diseases Pharmacologic Actions |